VeriFixxTM Small Bone Implant (VerioxTM Coated) Implant is indicated for the fixation of osteotomies/reconstruction of the lesser toes after corrective procedures for hammertoe, claw and mallet toe.
VeriCynTM Wound Wash is intended for moistening and debriding acute and chronic dermal lesions, such as pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions and minor skin irritations and intended to be used in conjunction with negative pressure wound therapy (NPWT).
VeriCyn™ for donor tissue is intended for eradicating bacteria, viruses, and fungi from both hard and soft donor tissues and organs. Donor tissues carrying various bacteria and/or viruses have the potential to transfer to the recipient. Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor–derived infections. Clinical Microbiology and Infection.2014;20(7):10-18. An unacceptable number of donations are rendered unusable due to the presence of pathogens. VeriCyn™ is being tested for use in donor sterilization by an international tissue bank.
– Veriox™ may be used as a coating and/or added to several products being researched and developed by ARMIS:
The first active agent from our platform technology, VERIOX™, has undergone significant pre-clinical efficacy and safety testing. Using VERIOX™ as our first-generation active agent, we intend VERIOX™ to target areas that are underserved in terms of new technology and clinical outcomes in the orthopedics, wound and surgical spaces.
We are pursuing three VERIOX™-containing medical products for uses in the wound, orthopedic and dermatology markets. Simultaneously with our product development efforts, we are beginning to develop the product manufacturing and commercialization infrastructure to bring our technology to market and to partner with other companies to bring value to their product lines.